Hansen Pharmaceuticals 2025 performance: revenue of 15.028 billion yuan, a growth of 22.6%, with innovative products accounting for as high as 82.2%.

Hansen Pharmaceuticals released its 2025 performance report, with annual revenue reaching 15.028 billion yuan, representing a year-on-year growth of 22.6%; net profit was 5.555 billion yuan, an increase of 27.1%, with a proposed dividend of 20 Hong Kong cents per share to reward all shareholders. Innovation and internationalization have become the core engines driving performance growth. In 2025, the company's revenue from innovative drugs and collaborative products reached 12.354 billion yuan, an increase of 30.4% year-on-year, with revenue accounting for 82.2%. Continued increase in research and development investment, with annual R&D expenses of 3.358 billion yuan, an increase of 24.3%, and revenue accounting for 22.3%. During the reporting period, 8 new innovative drug candidates entered clinical research for the first time, with 7 new phase III key registration clinical trials initiated, and over 70 innovative drug clinical trials progressed. Globalization accelerated breakthroughs, with Amelex obtaining approval for listing by the UK MHRA and EU EC, becoming the first Chinese original EGFR-TKI listed overseas; the company achieved three overseas authorizations during the year, with a total transaction value exceeding 4.54 billion US dollars. In addition, cash and deposits at the end of the year amounted to 31.549 billion yuan, providing solid support for future research and development, global expansion, and innovation transformation.